Donald Mahler
Pulmonary Disease · Lebanon, NHNPI 1518075159
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Boehringer Ingelheim at 35.2% of the total. Reporting peaked in 2019 at $186,132 and has fallen 94.2% since, to $10,764 in 2025. Among pulmonary disease clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 340 payments — averaging $1208.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$145K
- AstraZeneca$64K
- Mylan Specialty L.p.$56K
- Teva Pharmaceuticals USA, Inc.$32K
- Boehringer Ingelheim International GmbH$21K
- GSK$21K
- plus $73K from 13 others
Across 15 payments — averaging $37,821 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mylan Specialty L.p.$336K
- Viatris Specialty LLC$207K
- Boehringer Ingelheim$21K
- Teva Pharmaceuticals USA, Inc.$3K
What the payments were for
- Consulting fees$193,41747%
- Speaking & faculty fees$180,94344%
- Travel & lodging$31,2318%
- Food & beverage$5,1131%
- Education$710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 99 | $144,504 |
| AstraZeneca | 81 | $64,280 |
| Mylan Specialty L.p. | 62 | $55,539 |
| Teva Pharmaceuticals USA, Inc. | 11 | $31,794 |
| Boehringer Ingelheim International GmbH | 17 | $21,089 |
| GSK | 25 | $20,856 |
| Boehringer Ingelheim Do Brasil Quimica E Farmaceutical Ltda. | 10 | $18,386 |
| Orphai Therapeutics Inc. | 1 | $14,000 |
| Boehringer Ingelheim Mexico SA De CV | 8 | $10,322 |
| Mylan Inc. | 7 | $10,203 |
| Sunovion Pharmaceuticals Inc. | 6 | $8,410 |
| Boehringer Ingelheim Korea LTD. | 1 | $3,000 |
| Aero US Inc | 1 | $2,706 |
| Cipla USA Inc. | 1 | $2,500 |
| Sanofi | 1 | $2,250 |
| Viatris Specialty LLC | 5 | $499 |
| Chiesi USA, Inc. | 2 | $335 |
| Astrazeneca UK Limited | 1 | $90 |
| CSL Behring | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STIOLTO RESPIMAT$53,552
- Yupelri$49,882
- STIOLTO$35,106
- BREZTRI$16,339
- AirDuo Digihaler$15,284
- ProAir Digihaler$12,869
- BREZTRI AEROSPHERE$11,551
- SPIRIVA$10,980
- SPIRIVA RESPIMAT$10,862
- TRELEGY ELLIPTA$8,036
- FASENRA$6,625
- AEROGEN SOLO NEBULIZER SYSTEM$5,412
- LONHALA MAGNAIR$4,050
- AEROGEN USB CONTROLLER SYSTEM$2,706
- AEROGEN SOLO; AEROGEN ULTRA$2,706
- SYMBICORT$1,950
- AIRSUPRA$1,886
- ArmonAir Digihaler$1,659
- LATUDA$760
- NINTEDANIB$620
How this compares
$410,776 in reported general payments places this provider in the 95th percentile of 78 pulmonary disease providers in New Hampshire.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $188,891 |
| Dupixent SyringeDupilumab | 19 | $123,589 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 91 | $80,901 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 139 | $79,519 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 43 | $37,218 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 69 | $31,926 |
| Spiriva RespimatTiotropium Bromide | 43 | $28,404 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 28 | $19,059 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 45 | $18,653 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $13,783 |
| SymbicortBudesonide/Formoterol Fumarate | 31 | $13,713 |
| Fluticasone Propionate HfaFluticasone Propionate | 23 | $4,602 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $3,509 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 95 | $2,747 |
| Ventolin HfaAlbuterol Sulfate | 14 | $977 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $144,504 | $126,982210 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $20,856 | $126,610190 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $64,280 | $69,583119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 78 pulmonary disease providers in New Hampshire.
Other pulmonary disease in Lebanon
- Jeffrey StewartLebanon$30K
- Erik SwensonLebanon$29K
- Elliot BackerLebanon$24K
- H ParkerLebanon$13K
- Alex GiffordLebanon$8K
- Peter DelongLebanon$4K
- William WeissLebanon$1K
- John HoweLebanon$631
- John NuschkeLebanon$477
- James LeiterLebanon$77
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.